Hutchinson Financial Advisors INC Makes New Investment in Sanofi $SNY

Hutchinson Financial Advisors INC bought a new position in shares of Sanofi (NASDAQ:SNY) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 22,039 shares of the company’s stock, valued at approximately $1,065,000.

Other institutional investors have also recently bought and sold shares of the company. Accent Capital Management LLC acquired a new position in Sanofi during the first quarter worth about $29,000. Eastern Bank raised its stake in Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after acquiring an additional 300 shares in the last quarter. Ameritas Advisory Services LLC acquired a new position in Sanofi during the second quarter worth about $28,000. Banque Transatlantique SA acquired a new position in Sanofi during the first quarter worth about $33,000. Finally, Brentview Investment Management LLC acquired a new position in Sanofi during the first quarter worth about $42,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on SNY shares. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Sanofi currently has an average rating of “Buy” and a consensus target price of $62.67.

Sanofi Stock Performance

Shares of SNY stock opened at $50.58 on Friday. The business’s 50 day simple moving average is $48.69 and its 200 day simple moving average is $49.55. Sanofi has a one year low of $44.62 and a one year high of $60.12. The stock has a market capitalization of $124.20 billion, a PE ratio of 11.85, a PEG ratio of 1.38 and a beta of 0.51. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 24th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.60 by $0.10. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business had revenue of $14.53 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same period in the prior year, the business posted $2.25 earnings per share. The firm’s revenue was down 7.5% on a year-over-year basis. As a group, research analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.